S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead

Anebulo Pharmaceuticals (ANEB) Stock Forecast, Price & News

$2.38
+0.02 (+0.85%)
(As of 05/26/2023 08:46 PM ET)
Compare
Today's Range
$2.38
$2.38
50-Day Range
$2.06
$2.98
52-Week Range
$1.77
$7.00
Volume
700 shs
Average Volume
5,120 shs
Market Capitalization
$61.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Anebulo Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
194.1% Upside
$7.00 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.48) to ($0.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

409th out of 1,010 stocks

Pharmaceutical Preparations Industry

188th out of 494 stocks


ANEB stock logo

About Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.

Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANEB Stock News Headlines

15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03
See More Headlines
Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANEB Company Calendar

Last Earnings
11/12/2021
Today
5/28/2023
Fiscal Year End
6/30/2023
Next Earnings (Estimated)
9/08/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANEB
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+194.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-6,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.50 per share

Miscellaneous

Free Float
3,666,000
Market Cap
$61.00 million
Optionable
Not Optionable
Beta
-1.42

Key Executives

  • Dr. Joseph F. Lawler M.D. (Age 50)
    Ph.D., Founder & Chairman
    Comp: $11k
  • Mr. Simon J. Allen B.Sc. (Age 54)
    M.B.A., MBA, CEO & Director
    Comp: $450k
  • Mr. Rex Merchant CFA (Age 62)
    CFO & Sec.
    Comp: $275k
  • Dr. Kenneth C. Cundy Ph.D. (Age 63)
    Chief Scientific Officer
    Comp: $345.53k
  • Mr. Scott L. Anderson
    Head of Investor Relations & Public Affairs













ANEB Stock - Frequently Asked Questions

Should I buy or sell Anebulo Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANEB shares.
View ANEB analyst ratings
or view top-rated stocks.

What is Anebulo Pharmaceuticals' stock price forecast for 2023?

2 Wall Street analysts have issued 1-year price objectives for Anebulo Pharmaceuticals' shares. Their ANEB share price forecasts range from $6.00 to $8.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 194.1% from the stock's current price.
View analysts price targets for ANEB
or view top-rated stocks among Wall Street analysts.

How have ANEB shares performed in 2023?

Anebulo Pharmaceuticals' stock was trading at $2.4237 at the beginning of the year. Since then, ANEB stock has decreased by 1.8% and is now trading at $2.38.
View the best growth stocks for 2023 here
.

When is Anebulo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, September 8th 2023.
View our ANEB earnings forecast
.

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04.

When did Anebulo Pharmaceuticals IPO?

(ANEB) raised $21 million in an IPO on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company served as the underwriter for the IPO.

What is Anebulo Pharmaceuticals' stock symbol?

Anebulo Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANEB."

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anebulo Pharmaceuticals' stock price today?

One share of ANEB stock can currently be purchased for approximately $2.38.

How much money does Anebulo Pharmaceuticals make?

Anebulo Pharmaceuticals (NASDAQ:ANEB) has a market capitalization of $61.00 million. The company earns $-6,830,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How can I contact Anebulo Pharmaceuticals?

The official website for the company is www.anebulo.com. The company can be reached via phone at 512-598-0931 or via email at ybriggs@lhai.com.

This page (NASDAQ:ANEB) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -